LTR Pharma (ASX:LTP) EBIT per Share : A$ (TTM As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma EBIT per Share?

LTR Pharma's EBIT per Share for the six months ended in Jun. 2023 was A$-0.01. LTR Pharma does not have enough years/quarters to calculate its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for LTR Pharma's EBIT per Share or its related term are showing as below:

ASX:LTP's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.7
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

LTR Pharma's EBIT for the six months ended in Jun. 2023 was A$-1.46 Mil.

LTR Pharma EBIT per Share Historical Data

The historical data trend for LTR Pharma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma EBIT per Share Chart

LTR Pharma Annual Data

Trend

Jun21

Jun22

Jun23

EBIT per Share

-0.01

LTR Pharma Semi-Annual Data
	Jun21	Jun22	Jun23
EBIT per Share	-	-0.01	-0.01

LTR Pharma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

LTR Pharma's EBIT per Share for the fiscal year that ended in Jun. 2023 is calculated as

	EBIT per Share		(A: Jun. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.455	/	139.420
=	-0.01

LTR Pharma's EBIT per Share for the quarter that ended in Jun. 2023 is calculated as

	EBIT per Share		(Q: Jun. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.455	/	139.420
=	-0.01

LTR Pharma (ASX:LTP) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

LTR Pharma EBIT per Share Related Terms

Thank you for viewing the detailed overview of LTR Pharma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

LTR Pharma (ASX:LTP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

9A/204 Alice Street, Brisbane, QLD, AUS, 4000

Website

https://www.ltrpharma.com

LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines